Leadership Changes and Administrative Restructuring at the FDA
Introduction
The Food and Drug Administration (FDA) is currently going through a major leadership transition after the resignation of Commissioner Marty Makary and the removal of several high-ranking officials.
Main Body
The agency is currently experiencing instability due to a series of high-level departures. Following Commissioner Marty Makary's resignation on Tuesday, the FDA removed Dr. Tracy Beth Høeg and Katherine Szarama, the acting directors of the CDER and CBER centers. Additionally, Chief of Staff Jim Traficant was dismissed. These changes follow the earlier departure of Dr. Vinay Prasad. To keep the agency running, Kyle Diamantas has been appointed acting commissioner, while Dr. Mike Davis and Karim Mikhail have taken over leadership of CDER and CBER. This turnover is linked to a controversial approach to regulatory science. Under Commissioner Makary, the agency began announcing policy decisions—especially regarding COVID-19 vaccines for children and pregnant women—via social media and press releases instead of using traditional official processes. During this time, many career scientists were fired, and the administration appointed officials who shared their skepticism of public health mandates, even if those officials lacked government management experience. There is now significant tension between political appointees and career scientists. Internal reports suggest that Dr. Høeg attempted to link COVID-19 vaccines to child deaths without providing data and tried to change the vaccine schedule to match Danish standards, though these actions faced legal challenges. Furthermore, it is reported that Commissioner Makary's departure was caused by a dispute over the approval of flavored e-cigarettes. Consequently, the agency is facing a credibility crisis, as pharmaceutical companies and advocacy groups are concerned that the drug review process has become too political.
Conclusion
The FDA is currently operating without permanent leadership in its most important divisions while the administration looks for a Senate-confirmed commissioner to stabilize the agency.
Learning
💡 The 'Power Shift' Logic: Moving from A2 to B2
At the A2 level, you describe events simply: "People left the FDA. It was a problem." To reach B2, you must describe cause, effect, and connection using 'linking logic'.
⚡ The 'Connecting' Toolkit
Look at how the text connects a problem to a result. Instead of using only "and" or "because," the author uses Transition Markers:
- "Consequently..." Used to show a direct result.
- Example: The process became political; consequently, the agency lost credibility.
- "Furthermore..." Used to add a second, more serious point to an argument.
- Example: There was a dispute over vaccines; furthermore, there was a fight about e-cigarettes.
🛠️ Upgrade Your Vocabulary: Static vs. Dynamic
Stop using the word "change." B2 speakers use specific words depending on the type of change. Analyze these shifts from the text:
| A2 Simple Word | B2 Professional Upgrade | Why it's better |
|---|---|---|
| Change | Restructuring | It implies a planned organization change. |
| Moving/Leaving | Transition | It describes a process of moving from one state to another. |
| Problem | Instability / Crisis | It describes the intensity of the problem. |
🎓 Pro Tip: The 'Passive' Professionalism
Notice the phrase: "Kyle Diamantas has been appointed acting commissioner."
In B2 English, we often care more about the person receiving the action than the person doing it.
A2 Style: "The government appointed Kyle." (Focus on Government) B2 Style: "Kyle has been appointed." (Focus on Kyle's new role)
Try to spot this 'Passive' structure in the text whenever a professional title is mentioned!